Systemic Treatment of Renal Cell Cancer: A Comprehensive Review

Overview

Journal Cancer Treat Rev

Publisher Elsevier

Specialty Oncology

Date 2017 Sep 13

PMID 28898679

Citations 96

Authors

Amparo Sanchez-Gastaldo

Emmanuelle Kempf

Aranzazu Gonzalez Del Alba

Ignacio Duran

Affiliations

Soon will be listed here.

Abstract

Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.

Citing Articles

Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy.

Nagpal R, Campione M, Rebuzzi S, Fratino L, Rescigno P, Bracarda S Technol Cancer Res Treat. 2025; 24:15330338251316626.

PMID: 39989333 PMC: 11848895. DOI: 10.1177/15330338251316626.

Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.

Wang S, Zhang R, Wang S, Guo Q, Yin D, Song Y Front Pharmacol. 2024; 15:1309148.

PMID: 39534085 PMC: 11555396. DOI: 10.3389/fphar.2024.1309148.

Structure, Inhibitors, and Biological Function in Nervous System and Cancer of Ubiquitin-Specific Protease 46.

Thi Pham K, Tran M, Nam L, Pham P, Nguyen T Bioinform Biol Insights. 2024; 18:11779322241285982.

PMID: 39410943 PMC: 11475357. DOI: 10.1177/11779322241285982.

The role of circular RNA targeting IGF2BPs in cancer-a potential target for cancer therapy.

Luo X, Shi J, Wang S, Jin X J Mol Med (Berl). 2024; 102(11):1297-1314.

PMID: 39287635 DOI: 10.1007/s00109-024-02488-8.

APOBEC family reshapes the immune microenvironment and therapy sensitivity in clear cell renal cell carcinoma.

Huang G, Zhan X, Shen L, Lou L, Dai Y, Jiang A Clin Exp Med. 2024; 24(1):212.

PMID: 39249558 PMC: 11383847. DOI: 10.1007/s10238-024-01465-2.